Current role of surgery in the management of oropharyngeal cancer

Meghan T. Turner, James Kenneth Byrd, Robert L. Ferris

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

The 1990s saw an increased use of chemoradiotherapy protocols, commonly referred to as organ-sparing therapy, for the treatment of oropharyngeal cancer after the Groupe d'Oncologie Radiothérapie Tête etCou trial. Since that time, human papillomavirus-associated oropharyngeal squamous cell carcinoma has been identified as a unique disease, with improved survival regardless of treatment modality. The improved outcomes of this population has led to re-evaluation of treatment paradigms in the past decade, with a desire to spare young, humanpapillomavirus-positive patients the treatment-related toxicitiesof chemoradiotherapy and to use new minimally invasive surgical techniques to improve outcomes. Numerous retrospective and prospective studies have investigated the role of surgery in treatment of oropharyngeal carcinoma and have demonstrated equivalent oncologic outcomes and improved functional outcomes compared with chemoradiotherapy protocols. Ongoing and future clinical trials may help delineate the role of surgery in the future.

Original languageEnglish (US)
Pages (from-to)1175-1183
Number of pages9
JournalJournal of oncology practice
Volume12
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Oropharyngeal Neoplasms
Chemoradiotherapy
Organ Sparing Treatments
Therapeutics
Squamous Cell Carcinoma
Retrospective Studies
Clinical Trials
Prospective Studies
Carcinoma
Survival
Population

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Health Policy

Cite this

Current role of surgery in the management of oropharyngeal cancer. / Turner, Meghan T.; Byrd, James Kenneth; Ferris, Robert L.

In: Journal of oncology practice, Vol. 12, No. 11, 01.11.2016, p. 1175-1183.

Research output: Contribution to journalReview article

Turner, Meghan T. ; Byrd, James Kenneth ; Ferris, Robert L. / Current role of surgery in the management of oropharyngeal cancer. In: Journal of oncology practice. 2016 ; Vol. 12, No. 11. pp. 1175-1183.
@article{c63148909e994e00b27cf2448b8ec4db,
title = "Current role of surgery in the management of oropharyngeal cancer",
abstract = "The 1990s saw an increased use of chemoradiotherapy protocols, commonly referred to as organ-sparing therapy, for the treatment of oropharyngeal cancer after the Groupe d'Oncologie Radioth{\'e}rapie T{\^e}te etCou trial. Since that time, human papillomavirus-associated oropharyngeal squamous cell carcinoma has been identified as a unique disease, with improved survival regardless of treatment modality. The improved outcomes of this population has led to re-evaluation of treatment paradigms in the past decade, with a desire to spare young, humanpapillomavirus-positive patients the treatment-related toxicitiesof chemoradiotherapy and to use new minimally invasive surgical techniques to improve outcomes. Numerous retrospective and prospective studies have investigated the role of surgery in treatment of oropharyngeal carcinoma and have demonstrated equivalent oncologic outcomes and improved functional outcomes compared with chemoradiotherapy protocols. Ongoing and future clinical trials may help delineate the role of surgery in the future.",
author = "Turner, {Meghan T.} and Byrd, {James Kenneth} and Ferris, {Robert L.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1200/JOP.2016.015263",
language = "English (US)",
volume = "12",
pages = "1175--1183",
journal = "Journal of Oncology Practice",
issn = "1554-7477",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Current role of surgery in the management of oropharyngeal cancer

AU - Turner, Meghan T.

AU - Byrd, James Kenneth

AU - Ferris, Robert L.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The 1990s saw an increased use of chemoradiotherapy protocols, commonly referred to as organ-sparing therapy, for the treatment of oropharyngeal cancer after the Groupe d'Oncologie Radiothérapie Tête etCou trial. Since that time, human papillomavirus-associated oropharyngeal squamous cell carcinoma has been identified as a unique disease, with improved survival regardless of treatment modality. The improved outcomes of this population has led to re-evaluation of treatment paradigms in the past decade, with a desire to spare young, humanpapillomavirus-positive patients the treatment-related toxicitiesof chemoradiotherapy and to use new minimally invasive surgical techniques to improve outcomes. Numerous retrospective and prospective studies have investigated the role of surgery in treatment of oropharyngeal carcinoma and have demonstrated equivalent oncologic outcomes and improved functional outcomes compared with chemoradiotherapy protocols. Ongoing and future clinical trials may help delineate the role of surgery in the future.

AB - The 1990s saw an increased use of chemoradiotherapy protocols, commonly referred to as organ-sparing therapy, for the treatment of oropharyngeal cancer after the Groupe d'Oncologie Radiothérapie Tête etCou trial. Since that time, human papillomavirus-associated oropharyngeal squamous cell carcinoma has been identified as a unique disease, with improved survival regardless of treatment modality. The improved outcomes of this population has led to re-evaluation of treatment paradigms in the past decade, with a desire to spare young, humanpapillomavirus-positive patients the treatment-related toxicitiesof chemoradiotherapy and to use new minimally invasive surgical techniques to improve outcomes. Numerous retrospective and prospective studies have investigated the role of surgery in treatment of oropharyngeal carcinoma and have demonstrated equivalent oncologic outcomes and improved functional outcomes compared with chemoradiotherapy protocols. Ongoing and future clinical trials may help delineate the role of surgery in the future.

UR - http://www.scopus.com/inward/record.url?scp=85011575348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011575348&partnerID=8YFLogxK

U2 - 10.1200/JOP.2016.015263

DO - 10.1200/JOP.2016.015263

M3 - Review article

VL - 12

SP - 1175

EP - 1183

JO - Journal of Oncology Practice

JF - Journal of Oncology Practice

SN - 1554-7477

IS - 11

ER -